Fifteen new N-containing maltooligosaccharides were obtained using the chemoenzymatic method. Among these compounds, maltooligosaccharides having 6-amino-6-deoxy-D-sorbitol residue, (3R, 4R, 5R, 6S)-hexahydro-3, 4, 5, 6-tetrahydroxy-1H-azepine residue, and (3R, 5R)-3, 4, 5-trihydroxypiperidine residue at the reducing end showed strong inhibitory activities for human pancreatic α-amylase (HPA) (EC 3.2.1.1) and human salivary α-amylase (HSA). The administration of (3R, 4R, 5R, 6S)-hexahydro-3, 5, 6-trihydroxy-1H-azepine-4-yl O-α-D-glucopyranosyl-(1→4)-α-D-glucopyranoside (13, IC50=4.3×10-5M for HPA, IC50=8.2×10-5M for HSA) and (3R, 5R)-3, 5-dihydroxypiperidine-4-yl O-α-D-glucopyranosyl-(1→4)-α-D-glucopyranoside (18, IC50=3.4×10-5M for HPA, IC50=4.6×10-5M for HSA) to ICR mice suppressed postprandial hyperglycemia.
利用
化学酶法获得了 15 种新的含 N 的麦芽
寡糖。在这些化合物中,还原端具有 6-
氨基-6-脱氧-D-
山梨醇残基、(3R, 4R, 5R, 6S)-hexahydro-3, 4, 5, 6-tetrahydroxy-1H-azepine 残基和 (3R, 5R)-3, 4, 5-trihydroxypiperidine 残基的麦芽
寡糖对人胰腺
α-淀粉酶(HPA)(
EC 3.2.1.1)和人唾液
α-淀粉酶(H
SA)有很强的抑制活性。服用(3R, 4R, 5R, 6S)-六氢-3, 5, 6-三羟基-1H-氮杂卓-4-基 O-α-
D-吡喃葡萄糖苷-(1→4)-α-
D-吡喃葡萄糖苷(13,对 HPA 的 IC50=4.3×10-5M, 对 H
SA 的 IC50=8.2×10-5M for H
SA)和 (3R,5R)-3,5-二羟基
哌啶-4-基 O-α-
D-吡喃葡萄糖基-(1→4)-α-
D-吡喃葡萄糖苷(18,IC50=3.4×10-5M for HPA,IC50=4.6×10-5M for H
SA)给 ICR 小鼠服用可抑制餐后高血糖。